Acesso livre
Acesso livre

Farmácia/Notícias da Indústria

Pílula da Pfizer é o mais recente tratamento contra COVID a se mostrar promissor.

16 Nov, 2021 | 12:41h

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Merck v Pfizer: como os dois antivirais contra COVID funcionam e serão utilizados.

16 Nov, 2021 | 12:38h

Merck v Pfizer: here’s how the two new COVID antiviral drugs work and will be used – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Novo relatório da OMS mapeia as barreiras à disponibilidade de insulina e sugere ações que promovam o acesso universal – “100 anos depois de sua descoberta, a insulina ainda está fora do alcance de muitos que vivem com diabetes.”

16 Nov, 2021 | 12:34h

Comunicado de imprensa: New WHO report maps barriers to insulin availability and suggests actions to promote universal access – World Health Organization

Relatório: Keeping the 100-year-old promise: making insulin access universal – World Health Organization

Comentário: Half the People Living with Diabetes Can’t Afford Insulin, WHO Report Shows – Health Policy Watch

Conteúdos relacionados:

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

 

Comentário no Twitter (fio – clique para saber mais)

 

Revisão | Manejo glicêmico no diabetes: antigas e novas abordagens.

16 Nov, 2021 | 12:20h

Glycaemic management in diabetes: old and new approaches – The Lancet Diabetes & Endocrinology (necessário cadastro gratuito)

 

Comentário no Twitter

 

Estudo randomizado fase 4 | Administração de vacinas contra COVID-19 (AstraZeneca ou Pfizer) concomitantemente às vacinas contra influenza sazonal em adultos é segura e preserva a resposta imune de ambas as vacinas.

15 Nov, 2021 | 14:10h

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

Amplo estudo populacional mostra que infecção prévia por SARS-CoV-2 reduz o risco de infecção após vacina de mRNA.

15 Nov, 2021 | 14:08h

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Comentários:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Comentário no Twitter

 

Estudo populacional no Catar mostrou que a efetividade contra doença grave, crítica ou fatal induzida pela variante Delta do SARS-CoV-2 foi de 93,4% para a vacina da Pfizer e de 96,1% para a vacina da Moderna.

15 Nov, 2021 | 14:06h

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Comentário no Twitter

 

[Preprint] Risco de COVID-19 grave é raro entre pessoas com vacinação plena na Inglaterra.

15 Nov, 2021 | 14:01h

Comentário: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Estudo original: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

De acordo com estudo, vacinas contra SARS-CoV-2 são seguras e imunogênicas na maioria das pessoas com câncer.

15 Nov, 2021 | 13:56h

Comunicado de imprensa: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School

Estudo original: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

#AHA21 – Estudo randomizado | Entre crianças e adolescentes submetidos a rastreamento ecocardiográfico e diagnosticados com doença cardíaca reumática latente, antibioticoprofilaxia secundária com penicilina G benzatina por 2 anos foi associada com redução da progressão ecocardiográfica (0,8 vs, 8,2% no grupo controle).

15 Nov, 2021 | 13:53h

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentários:

Penicillin significantly reduces rheumatic heart disease progression in children – Murdoch Children’s Research Institute

Penicillin slows devastating impacts of rheumatic heart disease in children from Uganda – Children’s National Hospital

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease – American College of Cardiology

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.